Abstract P4-08-04: Navigating genomic landscape to find a PI3K-signaling algorithm for a rational combinatin in precision medicineJH Carlson, Brian Leyland‐Jones, Amy Krie et al.|Cancer Research|2016Cited by 0
Abstract P2-05-09: Vascular mimicry in metastatic breast cancer patients: Molecular insight to vascular mimicry using<i> in vitro</i> and<i> in vivo</i> modelsNandini Dey, BR Leyland-Jones, JH Carlson et al.|Cancer Research|2016Cited by 0
Abstract P6-08-03: Dynamics of cancer stem cell surface marker, CD44 and CD44v6 in the antitumor efficacy of PARP inhibitor in combination with PI3K pathway inhibitor in TNBC xenograft modelXiaoti Lin, Brian Leyland‐Jones, LS Friedman et al.|Cancer Research|2017Cited by 0
Abstract P1-03-02: Preclinical efficacy of a novel and potent inhibitor of the MDM2-p53 axis AMG 232 in ER+ breast cancer modelPK De, B Leyland-Jones, JH Carlson et al.|Cancer Research|2018Cited by 0
Abstract PD4-15: A tale of two pathways: Mutations in PI3K pathway in TNBC patients matter for the oncogenic cooperation with DNA damage repair pathwayNandini Dey, Brian Leyland‐Jones, Casey Williams et al.|Cancer Research|2018Cited by 0